CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

flurbiprofen

Trade name: ansaid

Small moleculeapproved

Approved

Dec 31, 1986

Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory drug that exhibits antiinflammatory, analgesic, and antipyretic activities in animal models. Flurbiprofen Tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and for relief of the signs and symptoms of osteoarthritis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity. — NCATS

Clinical trial activity

68 trials · 55 clinical orgs · 14 marketing orgs

Phase 1
27
Phase 2
11
Phase 3
4
Phase 4
11

Earliest trial started Nov 1, 1997 (NCT00001724)

Timeline

1980s

  1. Dec 31, 1986

    Earliest FDA Approval

  2. Dec 31, 1986

    Allergan — NDA Secondary Org

  3. Dec 31, 1986

    SmithKline Beckman — NDA Secondary Org

  4. Oct 31, 1988

    Pharmacia & Upjohn — First NDA Organization

  5. Oct 31, 1988

    Pharmacia & Upjohn — NDA Secondary Org

  6. Oct 31, 1988

    Pharmacia & Upjohn — NDA Organization

1990s

  1. Jun 20, 1994

    Mylan — Marketing Organization

  2. Jun 20, 1994

    Natco Pharma — Marketing Organization

  3. Jan 4, 1995

    Bausch & Lomb — Marketing Organization

  4. May 31, 1995

    Teva — Marketing Organization

  5. May 31, 1995

    Genus Oncology, LLC — Marketing Organization

  6. May 31, 1995

    NEW HEIGHTSRX — Marketing Organization

  7. Jul 28, 1995

    Aurobindo Pharma — Marketing Organization

  8. Jul 28, 1995

    Rising Pharmaceuticals — Marketing Organization

  9. Jan 1, 1997

    Earliest Phase 2 Sponsor(trial)

  10. Apr 1, 1997

    Pliva — Marketing Organization

  11. May 16, 1997

    Theragen — Marketing Organization

2000s

  1. Apr 27, 2001

    Sun Pharmaceuticals — Marketing Organization

  2. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewDec 31, 1986

Chemistry & pharmacology

Loading structure…

SMILES

CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1.O.O.[Na+]
Mol. weight
302.28 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 2-(2-fluorobiphenyl-4-yl)propanoic acid
  • 2-(2-fluorobiphenyl-4-yl)propanoic acid
  • 2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
  • 2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
  • (+-)-2-fluoro-alpha-methyl-4-biphenylacetic acid
  • (+-)-2-fluoro-alpha-methyl-4-biphenylacetic acid
  • (−)-(2r)-2-(2-fluorobiphenyl-4-yl)propanoic acid
  • (−)-(2r)-2-(2-fluorobiphenyl-4-yl)propanoic acid
  • (2r)-2-(2-fluorobiphenyl-4-yl)propanoic acid
  • (2r)-2-(2-fluorobiphenyl-4-yl)propanoic acid
  • 3-fluoro-4-phenylhydratropic acid
  • 3-fluoro-4-phenylhydratropic acid
  • ansaid
  • ansaid
  • ansaid
  • bts 18322
  • bts 18322
  • bts-18322
  • bts-18322
  • bts-24332
  • bts-24332
  • cebutid
  • cebutid
  • dl-flurbiprofen
  • flp
  • flp
  • flubiprofen
  • flubiprofen
  • flubiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • flurbiprofen
  • (+/-)-flurbiprofen
  • flurbiprofen axetil
  • flurbiprofen axetil
  • flurbiprofen axetil
  • flurbiprofen axetil
  • flurbiprofen axetil
  • flurbiprofene
  • flurbiprofene
  • flurbiprofeno
  • flurbiprofeno
  • flurbiprofen sodium
  • flurbiprofen sodium
  • flurbiprofen sodium
  • flurbiprofen sodium
  • flurbiprofenum
  • flurbiprofenum
  • fluribiprofen
  • fluribprofen
  • fluriprofen
  • fluroben
  • flurofen
  • froben
  • froben
  • froben sr
  • froben sr
  • occufen
  • ocufen
  • ocufen
  • pluronic lecithin organogel
  • ropiopn
  • strefen
  • strefen
  • transact
  • transact
  • u-27182
  • u-27182
  • zepolas
  • zepolas

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07223671Phase 1Nov 12, 2025Bristol-Myers Squibb
NCT07235748Phase 1Oct 7, 2025Servier
NCT07149545N/ASep 15, 2025Capital Medical University
NCT07163429N/ASep 10, 2025Chiangmai University
NCT06823284Phase 1Jan 21, 2025HWI pharma services GmbH, SocraMetrics GmbH, SocraTec R&D GmbH, Teikoku Seiyaku Co., Ltd.
NCT06531837N/AAug 25, 2024Capital Medical University
NCT06566794N/AAug 20, 2024University of Helsinki
NCT06238154Phase 4Oct 26, 2023Yuzuncu Yıl University
NCT05955885Early Phase 1 (Phase 1)Jul 1, 2023Reckitt Benckiser Pharmaceutical, University of Melbourne
NCT05932277Phase 1Jun 29, 2023Bristol-Myers Squibb
NCT05852769Phase 1May 31, 2023Bristol-Myers Squibb
NCT05981365Phase 1Apr 17, 2023Pfizer
NCT05624359N/AJan 1, 2023Capital Medical University
NCT06041178Phase 4Sep 30, 2022Beirut Arab University
NCT05504265Phase 2/Phase 3 (Phase 3)Aug 10, 2022Chinese Academy of Medical Sciences
NCT05254548Phase 1Feb 18, 2022Idorsia Pharmaceuticals Ltd.
NCT05512013Phase 1Feb 15, 2022United States Army
NCT06000137N/AFeb 10, 2022Fudan University
NCT04976790N/AAug 15, 2021Dongfang Hospital Beijing University of Chinese Medicine, Peking University
NCT04708964Phase 2Jan 31, 2021Universita' Cattolica del Sacro Cuore
Showing 20 of 68 trials
Page 1 / 4

Organizations

Research & Development (55)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit6612014
Capital Medical UniversityAcademic/Hospital6622018
Reckitt Benckiser PharmaceuticalFor profit4322009
Fudan UniversityAcademic/Hospital3312015
GlaxoSmithKlineFor profit3312006
People's Liberation Army of ChinaGovernment3212013
Chinese Medical AssociationAcademic/Hospital2212015
Dexcel Pharma Technologies Ltd.For profit2212008
Hebrew UniversityAcademic/Hospital2122008
Nanjing Medical UniversityAcademic/Hospital2222008
Peking UniversityAcademic/Hospital2222020
SocraMetrics GmbHFor profit2012020
SocraTec R&D GmbHFor profit2112020
Sun Yat-Sen UniversityAcademic/Hospital2212018
Teikoku Seiyaku Co., Ltd.For profit2112020
University of GenevaAcademic/Hospital2222009
AblivaFor profit1112020
AngeliniFor profit1112018
Anhui College of Traditional Chinese MedicineAcademic/Hospital1012016
Anhui Medical UniversityAcademic/Hospital1112016
55 organizations
Page 1 / 3

Marketing (16)

OrganizationOrg typeRelationshipDate
AllerganFor profitNDA2Dec 31, 1986
Aurobindo PharmaFor profitMKTGJul 28, 1995
Bausch & LombFor profitMKTGJan 4, 1995
Genus Oncology, LLCFor profitMKTGMay 31, 1995
MylanFor profitMKTGJun 20, 1994
NEW HEIGHTSRXFor profitMKTGMay 31, 1995
Natco PharmaFor profitMKTGJun 20, 1994
Pharmacia & UpjohnFor profitNDA2Oct 31, 1988
Pharmacia & UpjohnFor profitNDAOct 31, 1988
PlivaFor profitMKTGApr 1, 1997
Rising PharmaceuticalsFor profitMKTGJul 28, 1995
SmithKline BeckmanFor profitNDA2Dec 31, 1986
Sun PharmaceuticalsFor profitMKTGApr 27, 2001
TevaFor profitMKTGMay 31, 1995
TevaFor profitSYNMay 24, 1995
TheragenFor profitMKTGMay 16, 1997